Alef Rafael Severino

Hospital Amaral Carvalho

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Camila Marques Bertolucci

Hospital Amaral Carvalho

Camila Marques Bertolucci

Hospital Amaral Carvalho

Maura Rosane Valério Ikoma

Hospital Amaral Carvalho

ÉR

Éderson Roberto Mattos

Hospital Amaral Carvalho

J. Tosi

Hospital Amaral Carvalho

Patrícia F. R. Siqueira

Universidade Federal do Rio de Janeiro

T. Santos

Faculdade de Medicina de São José do Rio Preto

Berta S Santos

DASA (Brazil)

Andressa Oliveira Martin Wagner

Polydoro Ernani de São Thiago University Hospital

Maura Rosane Valerio Ikoma-Colturato

Hospital Amaral Carvalho

Cooperative Institutions

Hospital Amaral Carvalho

Hospital Israelita Albert Einstein

Universidade Estadual de Campinas (UNICAMP)

Universidade de São Paulo

Universidade Federal do Rio de Janeiro

University of Trás-os-Montes and Alto Douro

DASA (Brazil)

Hospital São Paulo

Hospital Erasto Gaertner

Hospital Universitário de Brasília

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Clinical validation of a 10-color flow cytometry panel to detect measurable residual disease in acute myeloid leukemia

Leukemia Research (2024)

Maura Rosane Valério Ikoma Alef Rafael Severino J. Tosi Camila Marques Bertolucci Yeda Midori Nakamura Cuoco

Minimal Residual Disease

10.1016/j.leukres.2024.107482

Cite

Citations (0)

Multicentric Standardization of Minimal/Measurable Residual Disease in Acute Myeloid Leukemia Using Multiparametric Flow Cytometry - a Brazilian Society of Bone Marrow Transplantation (SBTMO) Project

Blood (2024)

Felipe Magalhães Furtado Maura Valerio Ikoma Colturato Fabíola Gevert Maria Daniela Holthausen Perico Berta S Santos

Minimal Residual Disease

Hematologic Neoplasms

10.1182/blood-2024-210458

Cite

Citations (0)

CD30 NEGATIVE/CD4 POSITIVE CYTOTOXIC T CELL LYMPHOMA: A RARE CUTANEOUS LYMPHOPROLIFERATIVE DISORDER

Hematology Transfusion and Cell Therapy (2023)

Laís da Silva Pereira Luiz Gustavo Rodrigues Barbosa Camila Marques Bertolucci Alef Rafael Severino Marcia Higashi

There are few reports of primary cutaneous lymphomas with CD4 + / CD30 negative cytotoxic T cell immunophenotype. Primary CD30 negative cutaneous T lymphomas are rare and correspond to less than 5% of all cutaneous T-lymphomas. Cytotoxic CD4+ T cell lymphomas are also uncommon. We report the clinical characteristics, immunophenotype and outcome of a patient with this rare type of T cell proliferation. A 66 year-old male presented a two years history of widespread erythematous scaly rash and nodules on the skin of the chest, which biopsy showed an atypical lymphocytic infiltrate in the dermis with epidermotropism. Immunohistochemical staining showed positivity for CD2, CD3, CD4, CD7, and no expressions of CD8 and CD30. The histopathological conclusion was Mycosis Fungoides (MF). Bone marrow (BM) biopsy was normal at diagnosis. Peripheral blood immunophenotyping detected 88 small T cells per mL with weak expressions of CD2, CD3 and CD5, normal expressions of CD4, CD27, CD28, CD45RA and partial expressions of CD7, CD25, CD26, CD45RO, CD56. Therefore, this phenotype was not characteristic of Sezary cells. Despite successive treatments (PUVA plus corticosteroids, methotrexate plus interferon, CHOP), the patient developed a progressive disease with worsening of skin lesions, disseminated lymphadenopathy, fever, night sweats. Inguinal lymph node biopsy was compatible with large cell T cell lymphoma, with immunostaining positivity for CD3 and CD4 while CD8, CD 30 and ALK were negative. The BM immunophenotype revealed large T cells with expressions of CD2, CD3, CD4, CD11c, CD26, CD27, CD38, CD45, CD45RO, CD56, CD94, CD197, cyGranzyme and cyPerforin with monoclonal pattern by the expression of T-cell receptor β1 constant region (TRBC1). These cells did not express CD5, CD7, CD16, CD25, CD28, CD30, CD57, CD45RA, cyTCL1. The immunophenotype observed does not meet the criteria for MF diagnosis. The immunophenotype observed was compatible with monoclonal cytotoxic CD4 cells. The clinical and immunophenotypic features suggested that diagnosis of a rare case of CD30 negative Anaplastic Large Cell Lymphoma (ALCL) transformed from a small cell variant of ALCL, with an aggressive clinical course. The presence of cytotoxicity markers such as cyPerforin and cyGranzyme are related to greater cytolytic activity, which correlates with more aggressive clinical behavior.

Immunophenotyping

CD5

Peripheral T-cell lymphoma

Skin biopsy

10.1016/j.htct.2023.03.014

Cite

Citations (1)

Immunophenotypic markers for the evaluation of minimal/measurable residual disease in acute megakaryoblastic leukemia

Hematology Transfusion and Cell Therapy (2023)

Carina Maria Pinto Camila Marques Bertolucci Alef Rafael Severino J. Tosi Maura Rosane Valério Ikoma

Acute megakaryoblastic leukemia is characterized by heterogeneous biology and clinical behavior. Immunophenotypic characteristics include the expression of megakaryocytic differentiation markers (e.g. CD41, CD42a, CD42b, CD61) associated with immaturity markers (CD34, CD117, HLA-DR.........) and myeloid markers (e.g. CD13, CD33) and even with lymphoid cross-lineage markers (e.g. CD7, CD56). Although the diagnostic immunophenotype has already been well described, given the rarity of the disease, its immunophenotypic heterogeneity and post-therapeutic instability, there is no consensus on the combination of monoclonal markers to detect minimal/measurable residual disease (MRD). Currently, MRD is an important tool for assessing treatment efficacy and prognostic risk. In this study, we evaluated the immunophenotypic profile of MRD in a retrospective cohort of patients diagnosed with acute megakaryoblastic leukemia, to identify which markers, positive or negative, were more stable after treatment and which could be useful for MRD evaluation. The expression profile of each marker was evaluated in sequential MRD samples. In conclusion, the markers evaluated in this study can be combined in an MRD immunophenotypic panel to investigate for megakaryoblastic leukemia. Although this study is retrospective and some data are missing, the information obtained may contribute to prospective studies to validate more specific strategies in the detection of MRD in acute megakaryoblastic leukemia.

Acute megakaryoblastic leukemia

Immunophenotyping

CD117

Minimal Residual Disease

10.1016/j.htct.2023.09.2364

Cite

Citations (0)